126 related articles for article (PubMed ID: 16163434)
1. [Severe hyperkalemia associated to the use of losartan and spironolactone: case report].
Kauffmann R; Orozco R; Venegas JC
Rev Med Chil; 2005 Aug; 133(8):947-52. PubMed ID: 16163434
[TBL] [Abstract][Full Text] [Related]
2. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
Van Buren PN; Adams-Huet B; Nguyen M; Molina C; Toto RD
Clin J Am Soc Nephrol; 2014 Feb; 9(2):295-301. PubMed ID: 24408116
[TBL] [Abstract][Full Text] [Related]
3. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
[TBL] [Abstract][Full Text] [Related]
4. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.
Gwoo S; Kim YN; Shin HS; Jung YS; Rim H
Nephron Clin Pract; 2014; 128(3-4):381-6. PubMed ID: 25572273
[TBL] [Abstract][Full Text] [Related]
5. Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients.
Sakallı H; Baskın E; Bayrakcı US; Moray G; Haberal M
Exp Clin Transplant; 2014 Aug; 12(4):310-3. PubMed ID: 24447308
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System.
Chang AR; Sang Y; Leddy J; Yahya T; Kirchner HL; Inker LA; Matsushita K; Ballew SH; Coresh J; Grams ME
Hypertension; 2016 Jun; 67(6):1181-8. PubMed ID: 27067721
[TBL] [Abstract][Full Text] [Related]
8. Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
Erden I; Yalcin S; Ozhan H
Kardiol Pol; 2010 Sep; 68(9):1043-5; discussion 1046. PubMed ID: 20859899
[TBL] [Abstract][Full Text] [Related]
9. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.
Fujii H; Nakahama H; Yoshihara F; Nakamura S; Inenaga T; Kawano Y
Kobe J Med Sci; 2005; 51(1-2):1-6. PubMed ID: 16199929
[TBL] [Abstract][Full Text] [Related]
10. [A case of intraoperative hyperkalemia induced with administration of an angiotensin II receptor antagonist (AIIA) and intake of dried persimmons].
Miyahara Y; Miyazaki T; Tanaka Y; Uchida K; Tamura T; Masuda N; Yamashita S; Yonei A
Masui; 2004 May; 53(5):543-6. PubMed ID: 15198240
[TBL] [Abstract][Full Text] [Related]
11. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Khosla N; Kalaitzidis R; Bakris GL
Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
[TBL] [Abstract][Full Text] [Related]
12. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
Ribeiro SC; Figueiredo AE; Barretti P; Pecoits-Filho R; de Moraes TP;
Am J Nephrol; 2017; 46(2):150-155. PubMed ID: 28738355
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension.
Abolghasmi R; Taziki O
Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):75-8. PubMed ID: 21196617
[TBL] [Abstract][Full Text] [Related]
14. Syncope caused by iatrogenic hyperkalemia.
Giancaspro G; Suppa M; Genuini I; Caselli S; Fedele F
J Cardiovasc Med (Hagerstown); 2009 Jan; 10(1):72-4. PubMed ID: 19708228
[TBL] [Abstract][Full Text] [Related]
15. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
Bianchi S; Bigazzi R; Campese VM
Am J Kidney Dis; 2005 Jul; 46(1):45-51. PubMed ID: 15983956
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced hyperkalaemia is frequent.
Prescrire Int; 2007 Feb; 16(87):16. PubMed ID: 17323523
[TBL] [Abstract][Full Text] [Related]
17. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.
Wrenger E; Müller R; Moesenthin M; Welte T; Frölich JC; Neumann KH
BMJ; 2003 Jul; 327(7407):147-9. PubMed ID: 12869459
[No Abstract] [Full Text] [Related]
18. Hyperkalemia: a threat to RAAS inhibition?
Schrier RW
Nat Rev Nephrol; 2010 May; 6(5):245-6. PubMed ID: 20424624
[No Abstract] [Full Text] [Related]
19. [An elderly man with known heart failure admitted with cardiogenic shock].
Hovland A; Fagerheim AK; Hardersen R; Nielsen EW
Tidsskr Nor Laegeforen; 2010 Jul; 130(13):1352-4. PubMed ID: 20596117
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Walser M
N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873778
[No Abstract] [Full Text] [Related]
[Next] [New Search]
